2. Academic Validation
  3. Discovery of RO7185876, a Highly Potent γ-Secretase Modulator (GSM) as a Potential Treatment for Alzheimer's Disease

Discovery of RO7185876, a Highly Potent γ-Secretase Modulator (GSM) as a Potential Treatment for Alzheimer's Disease

  • ACS Med Chem Lett. 2020 Apr 27;11(6):1257-1268. doi: 10.1021/acsmedchemlett.0c00109.
Hasane Ratni 1,  Andre Alker 1,  Bjoern Bartels 1,  Caterina Bissantz 1,  Weichun Chen 2,  Irene Gerlach 1,  Anja Limberg 1,  Mingqiu Lu 2,  Werner Neidhart 1,  Solen Pichereau 1,  Michael Reutlinger 1,  Rosa-Maria Rodriguez-Sarmiento 1,  Roland Jakob-Roetne 1,  Georg Schmitt 1,  Eric Zhang 2,  Karlheinz Baumann 1
Affiliations

Affiliations

  • 1 F. Hoffmann-La Roche Ltd., pRED, Pharma Research & Early Development, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • 2 F. Hoffmann-La Roche Ltd., pRED, Pharma Research & Early Development, Roche Innovation Center Shanghai, Cai Lun Road 720, 201203 Shanghai, China.
PMID: 32551009 DOI: 10.1021/acsmedchemlett.0c00109
Abstract

γ-secretase (GS) is a key target for the potential treatment of Alzheimer's disease. While inhibiting GS led to serious side effects, its modulation holds a lot of potential to deliver a safe treatment. Herein, we report the discovery of a potent and selective gamma secretase modulator (GSM) (S)-3 (RO7185876), belonging to a novel chemical class, the triazolo-azepines. This compound demonstrates an excellent in vitro and in vivo DMPK profile. Furthermore, based on its in vivo efficacy in a pharmacodynamic mouse model and the outcome of the dose range finding (DRF) toxicological studies in two species, this compound was selected to undergo entry in human enabling studies (e.g., GLP toxicology and scale up activities).

Figures
Products